Registry study for people already treated with NeVa thrombectomy
Part of Brain & nervous system, Heart & circulation clinical trials.
This registry study follows people who have already had a specific clot-removal procedure using the NeVa device. It helps doctors understand how the device performs in real-world care for certain kinds of stroke.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You already received treatment with a NeVa clot-removal device
- Your stroke symptoms started within the last 24 hours (from “last known well”)
- Your stroke scan showed a large artery blockage (like parts of the middle or posterior circulation) and enough salvageable brain tissue
- Your neurologic severity was at least moderate (NIHSS score 6 or higher) and you had low disability before the stroke (mRS 0–1)
- You can give consent (or your legal representative can) within 72 hours after the procedure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study records outcomes for people having an acute ischemic stroke treated with an endovascular (catheter-based) procedure. It may help doctors understand how clot-removal treatment works in different patients and hospitals.
This registry tracks how Medtronic's FDA-approved devices work in treating acute ischemic stroke (a type of stroke caused by a blood clot) in everyday clinical practice. Researchers collect information to understand device safety and effectiveness outside of formal clinical trials.
This trial tests a device called the CONDA Stent Retriever to remove blood clots in people having a severe stroke caused by a blockage in a large brain artery. It may help if you can be treated within 24 hours of symptoms starting and meet specific brain scan and health criteria.
This trial tests if removing a large blood clot from the brain up to 3 days after a stroke improves recovery compared to standard medical care alone. It is for patients who have a severe stroke and are otherwise healthy enough for the procedure.
This Phase 2 trial tests whether the study medicine (LT3001) is safe and improves outcomes for people with an acute ischemic stroke who are getting a procedure to remove a clot (EVT). It aims to help certain patients who have a specific brain scan pattern soon after stroke symptoms start.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.